OverviewSuggest Edit

ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. The Company's most advanced product candidates are CF-301, a lysin for the treatment of Staph aureus bacteremia and CF-404, a cocktail of monoclonal antibodies for the treatment of life-threatening seasonal and pandemic varieties of influenza.

TypePublic
Founded2008
HQYonkers, US
Websitecontrafect.com
Employee Ratings2.5

Latest Updates

Employees (est.) (Mar 2020)24(+20%)
Job Openings3
Revenue (FY, 2017)$0
Share Price (Oct 2020)$5.3 (+2%)
Cybersecurity ratingAMore

Key People/Management at ContraFect

Roger J. Pomerantz

Roger J. Pomerantz

President, Chief Executive Officer and Chairman of the Board
David N. Low

David N. Low

Director
Michael J. Otto

Michael J. Otto

Director
Cary W. Sucoff

Cary W. Sucoff

Director
Cara Cassino

Cara Cassino

Chief Medical Officer and Executive Vice President of Research and Development
Sol Barer

Sol Barer

Lead Director
Show more

ContraFect Office Locations

ContraFect has an office in Yonkers
Yonkers, US (HQ)
28 Wells Ave
Show all (1)

ContraFect Financials and Metrics

ContraFect Revenue

USD

Net income (Q2, 2020)

(17.6m)

EBIT (Q2, 2020)

(8.2m)

Market capitalization (15-Oct-2020)

148.5m

Closing stock price (15-Oct-2020)

5.3

Cash (30-Jun-2020)

30.8m

EV

121.4m
ContraFect's current market capitalization is $148.5 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

8.1m10.1m11.4m9.2m8.7m9.8m

R&D expense

8.9m15.0m22.1m17.3m22.4m18.1m

Operating expense total

16.9m25.1m33.5m26.6m31.1m27.9m
Quarterly
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

1.2m2.3m2.3m2.9m2.4m4.7m2.5m1.9m2.1m2.3m1.8m2.2m2.1m2.3m2.6m2.4m3.0m2.6m

R&D expense

1.5m2.4m2.4m4.3m3.4m4.4m7.3m5.9m4.2m3.8m4.9m5.3m5.7m4.1m4.8m5.3m5.1m5.5m

Operating expense total

2.7m4.6m4.7m7.2m5.7m9.2m9.8m7.9m6.3m6.1m6.7m7.5m7.8m6.4m7.4m7.6m8.1m8.2m

EBIT

(2.7m)(4.6m)(4.7m)(7.2m)(5.7m)(9.2m)(9.8m)(7.9m)(6.3m)(6.1m)(6.7m)(7.5m)(7.8m)(6.4m)(7.4m)(7.6m)(8.1m)(8.2m)
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

25.7m10.0m3.8m7.0m8.3m24.2m

Prepaid Expenses

368.8k1.2m1.0m1.8m988.8k6.6m

Current Assets

27.8m34.1m36.2m48.7m31.4m30.8m

PP&E

2.1m1.6m1.3m1.1m1.1m1.1m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(30.1m)(25.1m)(28.5m)(15.5m)(37.7m)(12.8m)

Depreciation and Amortization

551.3k537.3k451.0k187.2k151.3k169.2k

Accounts Payable

(1.1m)600.4k649.0k324.2k1.1m(444.7k)

Cash From Operating Activities

(14.9m)(22.2m)(29.3m)(24.5m)(26.3m)(27.4m)
USDQ2, 2014

Debt/Equity

-0.2 x

Debt/Assets

1.5 x

Financial Leverage

-0.1 x
Show all financial metrics

ContraFect Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

ContraFect Online and Social Media Presence

Embed Graph

ContraFect News and Updates

ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation

Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caus…

ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update

Exebacase Phase 2 study results published in the Journal of Clinical Investigation

ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development

YONKERS, N.Y., July 20, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatenin…

Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremia

ContraFect Announces Appointment of Lishan Aklog, M.D. to Board of Directors

YONKERS, N.Y., June 15, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatenin…

ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc.

YONKERS, N.Y., May 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatment of life-threatening infectious diseases, today announced that Pfizer Inc. (NYSE: PFE) has entere…
Show more

ContraFect Blogs

ContraFect Frequently Asked Questions

  • When was ContraFect founded?

    ContraFect was founded in 2008.

  • Who are ContraFect key executives?

    ContraFect's key executives are Roger J. Pomerantz, David N. Low and Michael J. Otto.

  • How many employees does ContraFect have?

    ContraFect has 24 employees.

  • Who are ContraFect competitors?

    Competitors of ContraFect include Sovicell, Affilogic and Bioz.

  • Where is ContraFect headquarters?

    ContraFect headquarters is located at 28 Wells Ave, Yonkers.

  • Where are ContraFect offices?

    ContraFect has an office in Yonkers.

  • How many offices does ContraFect have?

    ContraFect has 1 office.